Press release
Anemia In Chronic Kidney Disease Pipeline Drugs Analysis Report, 2024 Updates: FDA Approvals, Clinical Trials, Therapies, MOA, RoA by DelveInsight | Jiangsu HengRui Medicine, Disc Medicine, 3SBio
The Anemia In Chronic Kidney Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
"Anemia In Chronic Kidney Disease Pipeline Insight, 2024 [https://www.delveinsight.com/sample-request/anemia-in-chronic-kidney-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Anemia In Chronic Kidney Disease Market.
Some of the key takeaways from the Anemia In Chronic Kidney Disease Pipeline Report:
* Companies across the globe are diligently working toward developing novel Anemia In Chronic Kidney Disease treatment therapies with a considerable amount of success over the years.
* Anemia In Chronic Kidney Disease companies working in the treatment market are Jiangsu HengRui Medicine, Disc Medicine, 3SBio, Kind Pharmaceuticals, Jiangsu Hansoh Pharmaceuticals, Genexine, and others, are developing therapies for the Anemia In Chronic Kidney Disease treatment
* Emerging Anemia In Chronic Kidney Disease therapies in the different phases of clinical trials are- DDO-3055, DISC 0974, SSS 17, AND017, Pegol-Sihematide, Efepoetin alfa, and others are expected to have a significant impact on the Anemia In Chronic Kidney Disease market in the coming years.
* In March 2024, Akebia Therapeutics Registered , Inc. (Nasdaq: AKBA), a biopharmaceutical company dedicated to improving the lives of individuals affected by kidney disease, has announced that the U.S. Food and Drug Administration (FDA) has granted approval for Vafseo Registered (vadadustat) Tablets. This medication is indicated for the treatment of anemia resulting from chronic kidney disease (CKD) in adults undergoing dialysis for a minimum of three months. Vafseo is an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor administered once daily, which triggers the body's response to hypoxia to stimulate natural erythropoietin production, thereby managing anemia. Vafseo has received approval in 37 countries.
* In April 2023, The Phase 3 clinical trial of GX-E4 (Efepoetin alfa), a potential treatment for anaemia brought on by chronic kidney disease, has revealed preliminary results, according to Genexine and its Asian regional partner, KG Bio. At the World Congress of Nephrology (WCN2023), its noninferiority results in comparison to Mircera (Methoxy Polyethylene Glycol-epoetin beta) were reported.
Anemia In Chronic Kidney Disease Overview
A frequent side effect of chronic kidney disease (CKD) is anaemia. renal disease (CKD) is characterised by impaired blood filtration due to renal injury. Waste and fluid might accumulate in the body as a result of this injury. Additional health issues can result from CKD.
Get a Free Sample PDF Report to know more about Anemia In Chronic Kidney Disease Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/anemia-in-chronic-kidney-disease-pipeline-insight [https://www.delveinsight.com/report-store/anemia-in-chronic-kidney-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Emerging Anemia In Chronic Kidney Disease Drugs Under Different Phases of Clinical Development Include:
* DDO-3055: Jiangsu HengRui Medicine
* DISC 0974: Disc Medicine
* SSS 17: 3SBio
* AND017: Kind Pharmaceuticals
* Pegol-Sihematide: Jiangsu Hansoh Pharmaceuticals
* Efepoetin alfa: Genexine
Anemia In Chronic Kidney Disease Route of Administration
Anemia In Chronic Kidney Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
* Oral
* Parenteral
* Intravenous
* Subcutaneous
* Topical
Anemia In Chronic Kidney Disease Molecule Type
Anemia In Chronic Kidney Disease Products have been categorized under various Molecule types, such as
* Monoclonal Antibody
* Peptides
* Polymer
* Small molecule
* Gene therapy
Anemia In Chronic Kidney Disease Pipeline Therapeutics Assessment
* Anemia In Chronic Kidney Disease Assessment by Product Type
* Anemia In Chronic Kidney Disease By Stage and Product Type
* Anemia In Chronic Kidney Disease Assessment by Route of Administration
* Anemia In Chronic Kidney Disease By Stage and Route of Administration
* Anemia In Chronic Kidney Disease Assessment by Molecule Type
* Anemia In Chronic Kidney Disease by Stage and Molecule Type
DelveInsight's Anemia In Chronic Kidney Disease Report covers around 10+ products under different phases of clinical development like
* Late-stage products (Phase III)
* Mid-stage products (Phase II)
* Early-stage product (Phase I)
* Pre-clinical and Discovery stage candidates
* Discontinued & Inactive candidates
* Route of Administration
Further Anemia In Chronic Kidney Disease product details are provided in the report. Download the Anemia In Chronic Kidney Disease pipeline report to learn more about the emerging Anemia In Chronic Kidney Disease therapies [https://www.delveinsight.com/sample-request/anemia-in-chronic-kidney-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Some of the key companies in the Anemia In Chronic Kidney Disease Therapeutics Market include:
Key companies developing therapies for Anemia In Chronic Kidney Disease are - FibroGen Inc, FortuneRock (China) Ltd, General Biologics Inc, Genexine Inc, Great Bay Bio Holdings Ltd, GSK plc, 3SBio Inc, Akebia Therapeutics Inc, Avesthagen Ltd, Biocad, Chong Kun Dang Pharmaceutical Corporation, Dong-A Socio Holdings Co Ltd, Jiangsu Hengrui Medicine Co Ltd, Liminal BioSciences Inc, Panacea Biotec Ltd, Panion & Bf Biotech Inc, PharmaEssentia Corp, PhytoHealth Corp, Jiangsu Hansoh Pharmaceutical Group Co Ltd, UBI Pharma Inc, Uni-Bio Science Group Ltd, Xenetic Biosciences Inc, Zosano Pharma Corp, Shanghai Chemo Wanbang Biopharma Co Ltd, SunBio Inc, HEC Pharma Co Ltd, HK inno.N Corp, Imagine Pharma LLC, InSilico Medicine, Japan Tobacco Inc, Jecho Biopharmaceuticals Co Ltd, Zydus Lifesciences Ltd, and others.
Anemia In Chronic Kidney Disease Pipeline Analysis:
The Anemia In Chronic Kidney Disease pipeline report provides insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Anemia In Chronic Kidney Disease with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Anemia In Chronic Kidney Disease Treatment.
* Anemia In Chronic Kidney Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Anemia In Chronic Kidney Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Anemia In Chronic Kidney Disease market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Anemia In Chronic Kidney Disease drugs and therapies [https://www.delveinsight.com/sample-request/anemia-in-chronic-kidney-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Anemia In Chronic Kidney Disease Pipeline Market Drivers
* Increase in the geriatric population with a higher risk of renal anemia due to age-related renal issues, increase in research and developmental activities are some of the important factors that are fueling the Anemia In Chronic Kidney Disease Market.
Anemia In Chronic Kidney Disease Pipeline Market Barriers
* However, high-cost associated with the disease, side effects associated with the disease and other factors are creating obstacles in the Anemia In Chronic Kidney Disease Market growth.
Scope of Anemia In Chronic Kidney Disease Pipeline Drug Insight
* Coverage: Global
* Key Anemia In Chronic Kidney Disease Companies: Jiangsu HengRui Medicine, Disc Medicine, 3SBio, Kind Pharmaceuticals, Jiangsu Hansoh Pharmaceuticals, Genexine, and others
* Key Anemia In Chronic Kidney Disease Therapies: DDO-3055, DISC 0974, SSS 17, AND017, Pegol-Sihematide, Efepoetin alfa, and others
* Anemia In Chronic Kidney Disease Therapeutic Assessment: Anemia In Chronic Kidney Disease current marketed and Anemia In Chronic Kidney Disease emerging therapies
* Anemia In Chronic Kidney Disease Market Dynamics: Anemia In Chronic Kidney Disease market drivers and Anemia In Chronic Kidney Disease market barriers
Request for Sample PDF Report for Anemia In Chronic Kidney Disease Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/anemia-in-chronic-kidney-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Table of Contents
1. Anemia In Chronic Kidney Disease Report Introduction
2. Anemia In Chronic Kidney Disease Executive Summary
3. Anemia In Chronic Kidney Disease Overview
4. Anemia In Chronic Kidney Disease- Analytical Perspective In-depth Commercial Assessment
5. Anemia In Chronic Kidney Disease Pipeline Therapeutics
6. Anemia In Chronic Kidney Disease Late Stage Products (Phase II/III)
7. Anemia In Chronic Kidney Disease Mid Stage Products (Phase II)
8. Anemia In Chronic Kidney Disease Early Stage Products (Phase I)
9. Anemia In Chronic Kidney Disease Preclinical Stage Products
10. Anemia In Chronic Kidney Disease Therapeutics Assessment
11. Anemia In Chronic Kidney Disease Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Anemia In Chronic Kidney Disease Key Companies
14. Anemia In Chronic Kidney Disease Key Products
15. Anemia In Chronic Kidney Disease Unmet Needs
16 . Anemia In Chronic Kidney Disease Market Drivers and Barriers
17. Anemia In Chronic Kidney Disease Future Perspectives and Conclusion
18. Anemia In Chronic Kidney Disease Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=anemia-in-chronic-kidney-disease-pipeline-drugs-analysis-report-2024-updates-fda-approvals-clinical-trials-therapies-moa-roa-by-delveinsight-jiangsu-hengrui-medicine-disc-medicine-3sbio]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Anemia In Chronic Kidney Disease Pipeline Drugs Analysis Report, 2024 Updates: FDA Approvals, Clinical Trials, Therapies, MOA, RoA by DelveInsight | Jiangsu HengRui Medicine, Disc Medicine, 3SBio here
News-ID: 3450927 • Views: …
More Releases from ABNewswire
Anything Named the #1 Vibe Coding Tool for Mobile Apps in a Comprehensive Indust …
San Francisco-based platform serves 500,000+ users with complete stack integration, autonomous debugging, and direct App Store deployment-distinguishing itself from prototype-focused competitors. Anything is thrilled to announce its recognition as the #1 vibe coding tool for mobile apps, establishing itself as the only platform that moves creators from idea to App Store to first customers without requiring engineering teams or external tool integration.
SAN FRANCISCO, CA - December 12, 2025 - Anything…
MyColoringPages Named the #1 AI Coloring Page Generator for Kids, Parents, and E …
Platform trusted by 20,000+ parents delivers custom coloring pages, complete storybooks, and photo-to-coloring conversion with industry-leading line quality and precision. MyColoringPages has been named the #1 AI Coloring Page Generator for Kids, Parents, and Educators.
New York, NY - December 12, 2025 - MyColoringPages is thrilled to announce its recognition as the #1 AI coloring page generator [https://songoftruth.org/perfect-ai-coloring-page-generators-for-kids-parents-who-want-endless-creativity/], establishing itself as the gold standard for parents, educators, and adults seeking endless…
Hashimoto's Thyroiditis Market to Show Remarkable Growth Trends from 2024 to 203 …
The Key Hashimoto's Thyroiditis Companies in the market include - TNF Pharmaceuticals, Sling Therapeutics, and others.
DelveInsight's "Hashimoto's Thyroiditis Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Hashimoto's Thyroiditis, historical and forecasted epidemiology as well as the Hashimoto's Thyroiditis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
The latest healthcare forecast report provides an in-depth analysis of Hashimoto's Thyroiditis,…
Paroxysmal Nocturnal Hemoglobinuria Market to Experience Notable Growth in Forec …
The Key Paroxysmal Nocturnal Hemoglobinuria Companies in the market include - Hoffmann-La Roche (Chugai Pharmaceutical), AstraZeneca (Alexion Pharmaceuticals), Apellis Pharmaceuticals, Swedish Orphan Biovitrum, Regeneron, Pharmaceuticals, Alnylam Pharmaceuticals, Omeros Corporation, BioCryst Pharmaceuticals, Novartis, Chengdu Suncadia Medicine Co., Ltd., Wuhan Createrna Science, Regeneron Pharma, Kira Pharma, NovelMed Therapeutics, and others.
DelveInsight's "Paroxysmal Nocturnal Hemoglobinuria Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Paroxysmal Nocturnal Hemoglobinuria, historical and forecasted…
More Releases for Anemia
Chemotherapy-Induced Anemia Market Forecast by Type Mild Moderate Severe and Lif …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Chemotherapy-Induced Anemia Market- (By Type of Anemia (Mild Anemia, Moderate Anemia, Severe Anemia, Life-Threatening Anemia), By Treatment Type (RBC Transfusion, Erythropoiesis-stimulating agents (ESAs), Iron Supplementation), By Drug Type (Epogen Injection, Procrit Injection, Androxy Oral, Aranesp Injection, Epoetin Alfa Injection, and Others), End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others)), By Region, Trends, Industry Competition…
Rising Cancer And Anemia Cases Propel Growth In Chemotherapy-Induced Anemia Mark …
The Chemotherapy-Induced Anemia Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Chemotherapy-Induced Anemia Market Size During the Forecast Period?
The Chemotherapy-Induced Anemia Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This…
Iron Deficiency Anemia Market Analysis 2034 | Iron Deficiency Anemia Therapies, …
As per DelveInsight, the Iron Deficiency Anemia Market is anticipated to grow immensely in the coming years owing to the launch of upcoming therapies and the increase in the incident population of Iron Deficiency Anemia in the 7MM.
DelveInsight's "Iron Deficiency Anemia Market Insights, Epidemiology, and Market Forecast 2034 [https://www.delveinsight.com/report-store/iron-deficiency-anemia-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Iron Deficiency Anemia market size,…
Aplastic Anemia Treatment Market - Shaping the Future of Aplastic Anemia Health: …
Newark, New Castle, USA: The "Aplastic Anemia Treatment Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors.
Aplastic Anemia Treatment Market: https://www.growthplusreports.com/report/aplastic-anemia-treatment-market/8435
This latest report researches the industry structure,…
Anemia Drugs Market 2018 Grow at CAGR of 8.4% to Reach USD 34.7 Billion | By Uni …
Market Research Future Published a Prime research Report on “Global Anemia Drugs Market Research Report - Forecast to 2022” – Market Analysis, Scope, Stake, Progress, Trends and Forecast to 2022
Global Anemia Drugs Market - Segments
Global anemia drugs market has been segmented on the basis of anemia type which comprises iron deficiency anemia, sickle cell anemia, aplastic anemia, hemolytic anemia pernicious anemia and others. On the basis of route of administration;…
Anemia in Chronic Kidney Disease (Renal Anemia) - Industry Analysis, Trends, and …
Market Research Hub (MRH) has recently announced the addition of a fresh report, titled “Anemia in Chronic Kidney Disease Pipeline Review, H1 2017” to its report offerings. The report provides an overview of the Anemia in Chronic Kidney Disease (Renal Anemia) (Hematological Disorders) pipeline landscape.
Request Free Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=1196648
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Anemia in Chronic Kidney Disease (Renal Anemia) - Pipeline Review, H1 2017,…
